Low-toxicity, long-circulating human interferon-alpha...

Details Low-toxicity, long-circulating human interferon-alpha... Low-toxicity, long-circulating human interferon-alpha...

2006-06-20

2010-02-16

Saoud, Christine J (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

C530S351000, C530S402000

Reexamination Certificate

active

07662370

ABSTRACT:
Interferon-alpha (IFNα) analog proteins modified by chemical attachment of at least one hydrophilic polymer moiety, such as polyethylene glycol chain, are described. In one embodiment, the IFNα analog protein has an amino acid sequence that differs from a native human IFNα interferon-alpha by one or more amino acid residues in the N-terminal region, comprised of between about residues 1-27, inclusive, by one or more substitutions selected based on the amino acid residue at the corresponding position of a mature interferon-tau (IFNτ) protein. Methods of treating viral diseases and other disorders with the polymer-modified IFNα analog protein are also described.

REFERENCES:
patent: 5281698 (1994-01-01), Nitecki
patent: 5362852 (1994-11-01), Geoghegan
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5711944 (1998-01-01), Gilbert et al.
patent: 5939286 (1999-08-01), Johnson et al.
patent: 5985265 (1999-11-01), Kinstler et al.
patent: 6113906 (2000-09-01), Greenwald et al.
patent: 6172046 (2001-01-01), Albrecht
patent: 6174996 (2001-01-01), Johnson et al.
patent: 6177074 (2001-01-01), Glue et al.
patent: 6204022 (2001-03-01), Johnson et al.
patent: 6531122 (2003-03-01), Pedersen et al.
patent: 6646110 (2003-11-01), Nissen et al.
patent: 6858409 (2005-02-01), Thompson et al.
patent: 6872393 (2005-03-01), Whitlow et al.
patent: 6982081 (2006-01-01), Sokawa et al.
patent: 7201897 (2007-04-01), Bailon et al.
patent: 2003/0049277 (2003-03-01), Sokawa et al.
patent: 2003/0130486 (2003-07-01), Villarete et al.
patent: 0240224 (1987-10-01), None
patent: WO03/016472 (2003-02-01), None
patent: WO/2004/022593 (2004-03-01), None
patent: WO2004/045648 (2004-06-01), None
patent: WO2004/084949 (2004-10-01), None
US 6,884,780, 04/2005, Drummond et al. (withdrawn)
Bailon et al., Rational Design of a Potent, Long-Lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol Conjugated Interferon alpha-2a for the Treatment of Hepatitis C. Bioconjugate Chem., 12, 196-202, 2001.
Meager A, Interferons alpha, beta and omega. Chapter 25 in “Cytokines”, Mire-Sluis AR and Thorpe R, eds, Academic press, San Diego, London, 1998, ISBN 0-12-498340-5, pp. 361-389.
Di Marco et al.,Journal of Medical Virology, 51:17-24 (1997).
Dieterich, Douglas. T., “HCV in HIV: Challenges and Opportunities,” http://www.prn.org/prn—nb—cntnt/vo16
um1/dieterich—sum.htm (2001).
Foser et al.,Protein Expression and Purification, 30:78-87 (2003).
Gomez, M. Romero,Rev Esp Enferm Dig(Madrid), 97(5):299-302 (2005).
Jensen et al.,European Journal of Gastroenterology&Hepatology, 17(9):899-904 (2005).
Manns et al.,The Lancet, 358:958-965 (2001).
Motzer et al.,Annals of Oncology, 13:1799-1805 (2002).
Osborn et al.,The Journal of Pharmacology and Experimental Therapeutics, 303(2):540-548 (2002).
Reddy et al.,Advanced Drug Delivery Reviews, 54:571-586 (2002).
Ward et al.,American Family Physician, 72(4):655-662 (2005).

Affiliated with

Also associated with

Rating

Low-toxicity, long-circulating human interferon-alpha... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Low-toxicity, long-circulating human interferon-alpha..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Low-toxicity, long-circulating human interferon-alpha... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4166826